Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a key player in the competitive landscape of biotech firms producing oncology therapeutics. With Brukinsa, their leading product generating a majority of their revenue, BeOne is expected to continue on a solid growth trajectory. However, there are potential risks and challenges, such as intellectual property and management execution, that the company will need to navigate as they pursue other treatments for various types of cancers.

Bears say

BeOne Medicines is led by Brukinsa (zanubrutinib), with global leadership in treating CLL that has a projected peak revenue of $6.8B by 2030. However, the company's other approved drugs generate most of their revenue from China, making them less competitive on a global scale. Issues with green manufacturing processes, clinical trial conduct, diversity, and socially responsible pricing could also pose challenges, despite strong financial results in 1Q exceeding estimates.

BeiGene Ltd (ONC) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 12 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $395.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $395.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.